Download Files:
Merestinib dihydrochloride
$132 – $768
Products Details
Product Description
– Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].
Web ID
– HY-15514A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C30H24Cl2F2N6O3
Citations
– Methods Mol Biol. 2018;1711:351-398.|Cancer Discov. 2016 Dec;6(12):1334-1341.|Clin Cancer Res. 2020 Jun 1;26(11):2615-2625.|Patent. WO2017019702A1.
References
– [1]Yan SB, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.|[2]Barat S, et al. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016 Jan 12.
CAS Number
– 1206801-37-7
Molecular Weight
– 625.45
Compound Purity
– 99.36
SMILES
– [H]Cl.[H]Cl.O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : ≥ 100 mg/mL
Target
– c-Met/HGFR;Discoidin Domain Receptor;FLT3;ROS Kinase
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
